Uncategorized
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
Jim Cramer recommends Union Pacific but is “getting tired of the orphan drug model.” Here’s what the “Mad Money” host said. read more
Demystifying Calix: Insights From 6 Analyst Reviews
Latest Ratings for CALX Date Firm Action From To Feb 2022 Loop Capital Initiates Coverage On Buy Jan 2022 Craig-Hallum Upgrades Hold Buy Oct 2021 Needham Maintains Buy View More Analyst Ratings for CALX View the Latest Analyst Ratings read more
IBM, Google Emerge As Top Investors In Quantum Computing With Most Patents Issued In 2025: ‘Only Two Companies Seriously Investing,’ Says Martin Shkreli
Out of the 300 quantum computing patents issued in 2025, IBM and Google are at the top. Here’s a list of other top investors in the field. read more
What Analysts Are Saying About Anglogold Ashanti Stock
Latest Ratings for AU Date Firm Action From To Mar 2022 Deutsche Bank Maintains Buy Mar 2022 JP Morgan Upgrades Neutral Overweight Feb 2022 JP Morgan Maintains Neutral View More Analyst Ratings for AU View the Latest Analyst Ratings read more
What Analysts Are Saying About DoubleVerify Holdings Stock
Latest Ratings for DV Date Firm Action From To Mar 2022 Canaccord Genuity Maintains Buy Mar 2022 RBC Capital Maintains Outperform Mar 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for DV View the Latest Analyst Ratings read more
Demystifying Biogen: Insights From 11 Analyst Reviews
Latest Ratings for BIIB Date Firm Action From To Mar 2022 Stifel Downgrades Buy Hold Mar 2022 RBC Capital Upgrades Sector Perform Outperform Feb 2022 Canaccord Genuity Maintains Buy View More Analyst Ratings for BIIB View the Latest Analyst Ratings read more